Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 10:2022:4264314.
doi: 10.1155/2022/4264314. eCollection 2022.

Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis

Marco Zuin  1 , Alessandro Trentini  2 , Judit Marsillach  3 , Andrea D'Amuri  1   4 , Cristina Bosi  1 , Loris Roncon  5 , Angelina Passaro  1   4   6 , Giovanni Zuliani  1   4 , Mike Mackness  7 , Carlo Cervellati  1
Affiliations
Review

Paraoxonase-1 (PON-1) Arylesterase Activity Levels in Patients with Coronary Artery Disease: A Meta-Analysis

Marco Zuin et al. Dis Markers. .

Abstract

Aim: To review and compare the PON-1 arylesterase activity between coronary artery disease (CAD) and non-CAD patients.

Methods: Data were obtained by searching MEDLINE and Scopus for all investigations published between January 1, 2000 and March 1, 2021 comparing PON-1 arylesterase activity between CAD and controls.

Results: Twenty studies, based on 5417 patients, met the inclusion criteria and were included in the analysis. A random effect model revealed that PON-1 arylesterase activity was significantly lower in the CAD group compared to controls (SMD = -0.587, 95%CI = -0.776 to -0.339, p < 0.0001, I 2 = 92.3%). In CAD patients, the PON-1 arylesterase activity was significantly higher among CAD patients without diabetes mellitus (DM) compared to those with diabetes (SMD: 0.235, 95% CI: 0.014 to 0.456, p = 0.03, I 2 = 0%).

Conclusions: PON-1 activity is significantly lower in CAD patients, and those without DM presented a significantly higher PON-1 arylesterase activity.

PubMed Disclaimer

Conflict of interest statement

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1
Figure 1
PRISMA flow chart.
Figure 2
Figure 2
Forest plot investigating the PON-1 arylesterase activity in coronary artery disease (CAD) patients and controls.
Figure 3
Figure 3
Forest plot of the PON-1 arylesterase activity in subjects with diabetes mellitus (DM) or nondiseased (no DM).
See this image and copyright information in PMC

References

    1. Oikonomou E., Siasos G., Tsigkou V., et al. Coronary artery disease and endothelial dysfunction: novel diagnostic and therapeutic approaches. Current Medicinal Chemistry . 2020;27(7):1052–1080. doi: 10.2174/0929867326666190830103219. - DOI - PubMed
    1. Izar M. C., Fonseca F. A. H., Ihara S. S. M., et al. Risk factors, biochemical markers, and genetic polymorphisms in early coronary artery disease. Arquivos Brasileiros de Cardiologia . 2003;80(4):379–395. doi: 10.1590/S0066-782X2003000400003. - DOI - PubMed
    1. Vassalle C., Petrozzi L., Botto N., Andreassi M. G., Zucchelli G. C. Oxidative stress and its association with coronary artery disease and different atherogenic risk factors. Journal of Internal Medicine . 2004;256(4):308–315. doi: 10.1111/j.1365-2796.2004.01373.x. - DOI - PubMed
    1. Misra M. K., Sarwat M., Bhakuni P., Tuteja R., Tuteja N. Oxidative stress and ischemic myocardial syndromes. Medical Science Monitor : International Medical Journal of Experimental and Clinical Research . 2009;15(10):RA209–RA219. - PubMed
    1. Mackness B., Mackness M. I., Arrol S., Turkie W., Durrington P. N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letters . 1998;423(1):57–60. doi: 10.1016/S0014-5793(98)00064-7. - DOI - PubMed

MeSH terms